Form D · Biotechnology
Pairidex Inc.
St. Louis, MO · CIK 0002056818
Offering snapshot reported Feb 20, 2025 · SEC filing
- Reported sold
- $1.09M Offering amount: $1.09M
- Investors reported
- 16 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- May 15, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 20, 2025 | Initial | $1,090,000 | No comparison | 16 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-538760
Source: Form D, filed Feb 20, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Todd Druley | Director |
| Allyson Mayer | Executive |
| Crystal Winkeler | Director |
| Andrew Young | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4340 Duncan Ave. Suite 213
St. Louis, MO, 63110
St. Louis, MO, 63110